Understand the source comparison
Research Peptides Same Pharmaceutical Difference: Manufacturing Comparison
Synthesis Method SPPS or liquid-phase, small batches (1–100g) SPPS or liquid-phase, validated scale-up (kg batches) 21 CFR 211 requires process validation for pharmaceuticals Identical chemistry; pharmaceutical adds process validation documentation Purity Stan
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Synthesis Method
- SPPS or liquid-phase, small batches (1–100g)
- SPPS or liquid-phase, validated scale-up (kg batches)
- 21 CFR 211 requires process validation for pharmaceuticals
- Identical chemistry; pharmaceutical adds process validation documentation
- Purity Standard
- 95–99% by HPLC (voluntary)
- 95–99% by validated HPLC per ICH Q2(R1)
- FDA requires validated analytical methods for drug approval
- Same target purity; pharmaceutical methods undergo third-party audit
- CoA Documentation
- Identity, purity, mass spec (standard)
- Identity, purity, sterility, endotoxin, residual solvents (required)
- USP <71> sterility, USP <85> endotoxin mandatory for pharmaceuticals
- Research CoAs may omit sterility/endotoxin unless voluntarily tested
- GMP Classification
- May follow GMP principles (voluntary)
- cGMP required, FDA-inspected facilities
- 21 CFR 210–211 mandatory for pharmaceutical manufacturing
- Research suppliers can match cGMP without FDA registration
- Stability Testing
- Typically not performed unless requested
- Forced degradation, ICH Q1A accelerated/long-term required
- FDA guidance requires 12–36 month stability data for NDA
- Biggest practical gap. Research peptides lack shelf-life validation
- Intended Use
- Laboratory research only
- Human therapeutic use
- 21 CFR 312.2(a) IND exemption vs approved drug status
- Legal use framework differs; molecule remains identical